Post-surgery samples revealed an increase of CTCs in 55.6% (5/9) of patients and changes in CTC subpopulations responded to 3 models: gain of PD-L1; gain of PD-L1 and BRAFV 600E or loss of both markers. Conclusion We optimized an antibody panel to evaluate BRAF V600E and PD-L1 expression on CTCs from early-stage CRC patients and we developed an efficient automatic analysis method, highlighting the importance of evaluating multiple parameters such as size, expression levels or protein localisation to identify intra and inter individual tumour heterogeneity.
over 2 years ago
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)